Ghassan K. Abou-Alfa, MD | Authors

Articles

Phase 3 REFLECT Trial in Unresectable HCC

June 23, 2021

Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.